TheraRadar
Data updated: May 26, 2026

LEVOCETIRIZINE HYDROCHLORIDE (levocetirizine dihydrochloride)

Trial Activity: Stable 2 active trials
Respiratory Approved 2019-04-01

LEVOCETIRIZINE HYDROCHLORIDE is indicated for the treatment of Hay Fever.

Source: FDA Label • HETERO LABS LTD III

Development Insights

UCB Pharma conducting 2 trials (40%)
4 indications explored (Focused)
seasonal allergic rhinitis (2 trials)
allergic asthma (1 trials)
breast cancer (1 trials)
1
Indication
--
Phase 3 Trials
7
Years on Market

Details

Status
Prescription
First Approved
2019-04-01
Routes
ORAL
Dosage Forms
SOLUTION

Companies

Active Ingredient: LEVOCETIRIZINE DIHYDROCHLORIDE

LEVOCETIRIZINE HYDROCHLORIDE Approval History

2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
3 FDA actions from 2019 to 2025
Jul 2025 SUPPL
Label · Labeling
Sep 2019 SUPPL
Label · Labeling
Apr 2019 ORIGINAL
Update

What LEVOCETIRIZINE HYDROCHLORIDE Treats

1 indications

LEVOCETIRIZINE HYDROCHLORIDE is approved for 1 conditions since its original approval in 2019. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Hay Fever
Source: FDA Label

LEVOCETIRIZINE HYDROCHLORIDE Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to LEVOCETIRIZINE HYDROCHLORIDE

3 of 19

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ADVAIR DISKUS 100/50
FLUTICASONE PROPIONATE
1 shared
GSK
Shared indications:
ADVAIR DISKUS 250/50
FLUTICASONE PROPIONATE
1 shared
GSK
Shared indications:
ADVAIR DISKUS 500/50
FLUTICASONE PROPIONATE
1 shared
GSK
Shared indications:
📋

Clinical Trial Registry

5 trials
Trial Sponsor ID Phase Status Title
NCT04699604 HAS3 STUDY00001262 5R01HD100545-05 Ph 3 recruiting A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3)
NCT06632405 CAnTiH Ph 2 not yet recruiting A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC
NCT00621959 results posted A00430 Ph 4 completed A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis
NCT01567501 Ipca/ARL/059 Ph 1 completed Bioequivalence Study of Levocetirizine Dihydrochloride Tablets 5 mg Under Fed Condition
NCT00653224 results posted A00431 Ph 4 completed A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

LEVOCETIRIZINE HYDROCHLORIDE FDA Label Details

Indications & Usage

LEVOCETIRIZINE HYDROCHLORIDE is indicated for the treatment of Hay Fever.

Track LEVOCETIRIZINE HYDROCHLORIDE with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.

How We Calculate These Metrics

Trial Activity Stage

Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.

Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.

  • Growth: High proportion of early-phase trials (Phase 1/2), active development
  • Expansion: Significant Phase 3 activity, approaching or pursuing approvals
  • Mature: Substantial Phase 4 post-marketing studies
  • Stable: Mixed phase distribution, steady development
  • Declining: Low active trial ratio, reduced R&D investment